<?xml version='1.0' encoding='utf-8'?>
<document id="16291876"><sentence text="Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists."><entity charOffset="113-123" id="DDI-PubMed.16291876.s1.e0" text="probenecid" /></sentence><sentence text="The renal drug-drug interaction between famotidine (an H(2) receptor antagonist) and probenecid has not been reproduced in rats"><entity charOffset="40-50" id="DDI-PubMed.16291876.s2.e0" text="famotidine" /><entity charOffset="85-95" id="DDI-PubMed.16291876.s2.e1" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.16291876.s2.e0" e2="DDI-PubMed.16291876.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16291876.s2.e0" e2="DDI-PubMed.16291876.s2.e1" /></sentence><sentence text=" We have proposed that this is caused by a species difference in the transport activity by human/rat organic anion transporter (OAT) 3 and the expression of organic cation transporter (OCT) 1 in the rodent kidney" /><sentence text=" Since monkey OATs (mkOATs) exhibit similar transport activities to human orthologs, it is hypothesized that in vivo studies in monkeys will allow a more precise prediction of renal drug-drug interactions in humans" /><sentence text=" Famotidine and cimetidine were efficiently taken up by mkOAT3-expressing human embryonic kidney cells (Km, 154 and 71 microM, respectively), and their uptake was strongly inhibited by probenecid (Ki, 3"><entity charOffset="1-11" id="DDI-PubMed.16291876.s5.e0" text="Famotidine" /><entity charOffset="16-26" id="DDI-PubMed.16291876.s5.e1" text="cimetidine" /><pair ddi="false" e1="DDI-PubMed.16291876.s5.e0" e2="DDI-PubMed.16291876.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16291876.s5.e0" e2="DDI-PubMed.16291876.s5.e1" /></sentence><sentence text="0-5" /><sentence text="7 microM)" /><sentence text=" Quantification of mkOCT1 and mkOCT2 mRNAs in the monkey kidney using real-time reverse transcription-polymerase chain reaction revealed their predominant expression in the liver and kidney, respectively" /><sentence text=" Crossover studies were conducted in cynomolgus monkeys" /><sentence text=" Famotidine was given by i"><entity charOffset="1-11" id="DDI-PubMed.16291876.s10.e0" text="Famotidine" /></sentence><sentence text="v" /><sentence text=" administration, with or without probenecid"><entity charOffset="33-43" id="DDI-PubMed.16291876.s12.e0" text="probenecid" /></sentence><sentence text=" Probenecid treatment caused a 65% reduction in the renal clearance (0"><entity charOffset="1-11" id="DDI-PubMed.16291876.s13.e0" text="Probenecid" /></sentence><sentence text="426 +/- 0" /><sentence text="079 versus 0" /><sentence text="165 +/- 0" /><sentence text="027 l/h/kg) and a 90% reduction in the tubular secretion clearance (0" /><sentence text="275 +/- 0" /><sentence text="075 versus 0" /><sentence text="0230 +/- 0" /><sentence text="0217 l/h/kg), whereas it had no effect on the renal clearance of cimetidine"><entity charOffset="65-75" id="DDI-PubMed.16291876.s21.e0" text="cimetidine" /></sentence><sentence text=" In contrast to the species-dependent effect of probenecid, allometric scaling using animal data (rat, dog, and monkey) successfully predicted the renal and tubular secretion clearance of famotidine in humans"><entity charOffset="48-58" id="DDI-PubMed.16291876.s22.e0" text="probenecid" /><entity charOffset="188-198" id="DDI-PubMed.16291876.s22.e1" text="famotidine" /><pair ddi="false" e1="DDI-PubMed.16291876.s22.e0" e2="DDI-PubMed.16291876.s22.e0" /><pair ddi="false" e1="DDI-PubMed.16291876.s22.e0" e2="DDI-PubMed.16291876.s22.e1" /></sentence><sentence text=" These results suggest that monkeys are more appropriate animal species for predicting the renal drug-drug interactions in humans" /><sentence text="" /></document>